CSPC Pharmaceutical Group Limited Informations sur les dividendes
CSPC Pharmaceutical Group Limited a un dividende annuel de 0.15 par action, avec un rendement de 0.00%. Le dividende est payé semestriellement et la dernière date d'ex-dividende était le Oct 20, 2025.
Rendement en dividend
Dividende annuel
Date ex-dividende
0.00%
$0.15
Oct 20, 2025
Fréquence des paiements
Taux de distribution
Semestriellement
0.00%
Historique des dividendes
Date ex-dividende
Montant en espèces
Date de registre
Date de paiement
Oct 20, 2025
$0.0717
Oct 20, 2025
Dec 3, 2025
Jun 5, 2025
$0.0514
Jun 5, 2025
Aug 1, 2025
Nov 1, 2024
$0.0821
Nov 1, 2024
Dec 5, 2024
Jun 3, 2024
$0.0716
Jun 3, 2024
Jul 11, 2024
Sep 7, 2023
$0.0715
Sep 8, 2023
Oct 26, 2023
Jun 5, 2023
$0.0561
Jun 6, 2023
Jul 13, 2023
Graphiques des dividendes
CSPCY Dividendes
CSPCY Croissance des dividendes (variation annuelle)
Follow-Up Questions
Quel est le dividende actuel payé par CSPC Pharmaceutical Group Limited et son dividende annuel ?
Le dividende actuel payé par CSPC Pharmaceutical Group Limited est de $0.0717. Le dividende annuel pour CSPC Pharmaceutical Group Limited est de $0.15
Quel est le ratio de distribution de dividendes de CSPC Pharmaceutical Group Limited ?
Le ratio de distribution de dividendes pour CSPC Pharmaceutical Group Limited est de 0.00%
Quelle est la date ex-dividende pour CSPCY ?
La date ex-dividende pour CSPC Pharmaceutical Group Limited est Oct 20, 2025.
À quelle fréquence CSPC Pharmaceutical Group Limited verse-t-elle des dividendes ?
Trimestriel. La dernière fois que CSPC Pharmaceutical Group Limited a versé un dividende était le Dec 3, 2025
Statistiques clés
Clôture préc.
$4.12
Prix d'ouverture
$4.15
Plage de la journée
$4.15 - $4.15
Plage de 52 semaines
$2.73 - $5.83
Volume
100
Volume moyen
3.5K
Rendement en dividend
--
BPA (TTM)
0.20
Capitalisation boursière
$11.8B
Qu’est-ce que CSPC Pharmaceuticals Group Ltd. ?
CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. The company is headquartered in Shijiazhuang, Hebei and currently employs 21,400 full-time employees. The firm operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Company’s product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The firm conducts its business in the domestic and overseas markets.